Mesoblast and oaktree extend availability period of undrawn tranches of financing facility

New york, dec. 22, 2022 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that funds managed by oaktree capital management, l.p. (“oaktree”) have extended to mesoblast the availability of up to an additional us$30.0 million of its us$90 million five year facility subject to achieving certain milestones on or before september 30, 2023.
MESO Ratings Summary
MESO Quant Ranking